Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Annual Pap Tests Are a Thing of the Past

By LabMedica International staff writers
Posted on 21 Nov 2012
New guidelines by The American College of Obstetricians and Gynecologists (ACOG; Washington, DC, USA) recommend that women should be normally screened for cervical cancer every three to five years at most.

According to the new guidelines, women under the age of 21, even if they have had sexual intercourse, should not be tested for cervical cancer or human papillomavirus (HPV). More...
This is because invasive cervical cancer is unusual in females younger than 21, even though HPV is common among sexually active teens. Most cervical abnormalities that are associated with HPV infection typically clear up on their own, making no treatment necessary. The College recommends that women ages 21 to 29 should no longer be tested for cervical cancer every two years, but once every three years.


Women aged 30 to 65 will see the biggest change in their screening guidelines. If they have negative results, they will be co-tested with the Pap test (the traditional or liquid-based method) along with HPV test once every five years. If HPV screening is not accessible, a Pap test by itself is sufficient once every three years.

Women older than 65 should no longer receive screening for cervical cancer if they have no history of cervical cancer; no history of cervical intraepithelial neoplasia (CIN) 2 or CIN 3; no history of adenocarcinoma in situ; if they have had three consecutive negative Pap test results, or two consecutive negative co-test results within the past 10 years, with the most recent test within the previous five years. Women, no matter what age, should discontinue routine screening if they have no history of CIN 2 or CIN 3, and who have had a hysterectomy with removal of the cervix (total hysterectomy).

Additionally, HPV-vaccinated women should follow the same guidelines as those who are unvaccinated. The recommendations are not meant for women who are immune-compromised, HIV-positive, or were exposed to diethylstilbestrol (DES) in utero. These females may need more to be tested more often. The new guidelines were published in the November 2012 issue of Obstetrics & Gynecology, and they are similar to the recommendations announced by the American Society for Colposcopy and Cervical Pathology (Frederick, MD, USA), the American Cancer Society, and other medical associations earlier in 2012.

“These recommendation changes are significant for physicians and patients alike. It will take some time and a lot of effort to re-educate everyone that the annual Pap is no longer the standard of care. It is critical, however, that women understand that their annual well-woman visit is still very important for many other aspects of their health care,” said David Chelmow, MD, who led the development of the ACOG guidelines.

Related Links:
The American College of Obstetricians and Gynecologists
American Society for Colposcopy and Cervical Pathology



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.